David C. Perlman, MD
CDUHR - Director, Infectious Disease Epidemiology and Theory Core
Mount Sinai Health System - Professor of Medicine, Icahn School of Medicine
Mount Sinai Health System - Chief, Infectious Diseases, Mount Sinai Beth Israel
MD, Medicine, Albert Einstein College of Medicine
BA. Biochemistry & Anthropology, Dartmouth College
Research Interests
HIV, HCV, IDUs, Diagnosis and treatment
David Perlman has over 20 years’ experience in HIV, HCV, TB and STIs and remains active as a clinician in these areas. He has served as principal investigator on multi-center trials within NIAID’s AIDS Clinical Trials group, and on R01 grants from NIDA. He has served on NIH study sections, CDC consensus panels, and committees within the ACTG, the NYS DOH AIDS Institute, and the NYC DOMH. Dr. Perlman’s earlier work focused on studies of the epidemiology of tuberculosis among drug users, and on health care delivery models and behavioral and structural interventions to facilitate adherence to the TB and HIV/TB care continuum. Dr. Perlman’s recent work has focused on studies of barriers and facilitators of HIV and HCV testing and care among racial and ethnic minorities, high risk heterosexuals, and people who use drugs, and more broadly on studies of strategies to improve HIV and HIV/HCV care continua and prevention programming for these populations.
Principal Investigator, Hepatitis Care Coordination in Methadone Treatment. Completed


Des Jarlais DC, Arasteh K, Feelemyer J, McKnight C, Barnes DM, Perlman DC, Uuskula A, Cooper HLF, Tross S (2018).
Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: Protective effects of non-injecting drug use
Drug and Alcohol Dependence, 192, 74-79. doi: 10.1016/j.drugalcdep.2018.07.034. PMCID: PMC6206865.

Behrends CN, Nugent AV, Des Jarlais DC, Frimpong JA, Perlman DC, Schackman BR (2018).
Availability of HIV and HCV on-site testing and treatment at syringe service programs in the United States
Journal of Acquired Immune Deficiency Syndromes, 79 (2), e76-e78. doi: 10.1097/QAI.0000000000001792.

Jordan AE, Perlman DC, Smith DJ, Hagan H (2018).
Application of an adapted PRECIS-2 instrument to assess efficacy- and effectiveness-study designs in a systematic review of intervention studies of the hepatitis C virus-care continuum among people who use drugs
Comparative Effectiveness Research, 8, 3-12. doi: 10.2147/CER.S145672.

Perlman DC, Jordan AE (2018).
The syndemic of opioid misuse, overdose, HCV, and HIV: Structural-level causes and interventions
Current HIV/AIDS Reports, 15 (2), 96-112. doi: 10.1007/s11904-018-0390-3. PMCID: PMC5884743.

Schackman BR, Gutkind S, Morgan JR, Leff JA, Behrends CN, Delucchi KL, McKnight C, Perlman DC, Masson CL, Linas BP (2018).
Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs
Drug and Alcohol Dependence PMC5889754. doi: 10.1016/j.drugalcdep.2017.11.031.

Dr. Perlman's MyBibliography Profile